Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 2156273, 17 pages
http://dx.doi.org/10.1155/2016/2156273
Review Article

Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory

1Ophthalmology Service, University Hospital Sant Joan, Institut de Investigacio Sanitaria Pere Virgili (IISPV), University of Rovira & Virgili, Reus, Spain
2Department of Ophthalmology, Retina Section, Hospital Universitario de Canarias, Tenerife, Spain
3Department of Ophthalmology, University Hospital Valladolid, Ocular Diabetes Unit of IOBA, Valladolid, Spain

Received 31 May 2016; Revised 29 August 2016; Accepted 6 September 2016

Academic Editor: Goran Petrovski

Copyright © 2016 Pedro Romero-Aroca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 6th edition, 2013, http://www.idf.org/diabetesatlas.
  2. R. R. A. Bourne, G. A. Stevens, R. A. White et al., “Causes of vision loss worldwide, 1990-2010: A systematic analysis,” The Lancet Global Health, vol. 1, no. 6, pp. e339–e349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Romero-Aroca, S. De La Riva-Fernandez, A. Valls-Mateu, R. Sagarra-Alamo, A. Moreno-Ribas, and N. Soler, “Changes observed in diabetic retinopathy: eight-year follow-up of a Spanish population,” British Journal of Ophthalmology, vol. 100, no. 10, pp. 1366–1371, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Romero-Aroca, “Targeting the pathophysiology of diabetic macular edema,” Diabetes Care, vol. 33, no. 11, pp. 2484–2485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Diabetic Retinopathy Guidelines, “The Royal College of Ophthalmologists,” December 2012, https://www.rcophth.ac.uk/.
  6. J. A. Wells, A. R. Glassman, A. R. Ayala et al., “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema,” The New England Journal of Medicine, vol. 372, pp. 1193–1203, 2015. View at Publisher · View at Google Scholar
  7. G. Staurenghi, S. Sadda, U. Chakravarthy, and R. F. Spaide, “International Nomenclature for Optical Coherence Tomography (INOCT) Panel. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the INOCT consensus,” Ophthalmology, vol. 121, no. 8, pp. 1572–1578, 2014. View at Publisher · View at Google Scholar
  8. J. Cunha-Vaz, R. Bernardes, and C. Lobo, “Blood-retinal barrier,” European Journal of Ophthalmology, vol. 21, supplement 6, pp. S3–S9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. J. Rizzolo, S. Peng, Y. Luo, and W. Xiao, “Integration of tight junctions and claudins with the barrier functions of the retinal pigment epithelium,” Progress in Retinal and Eye Research, vol. 30, no. 5, pp. 296–323, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Klaassen, C. J. F. Van Noorden, and R. O. Schlingemann, “Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions,” Progress in Retinal and Eye Research, vol. 34, pp. 19–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Zhang and B. R. Bhavnani, “Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as Apoptosis Inducing Factor (AIF) and this process is inhibited by equine estrogens,” BMC Neuroscience, vol. 7, article 49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. L. P. Aiello and DCCT/EDIC Research Group, “Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study,” Diabetes Care, vol. 37, no. 1, pp. 17–23, 2014. View at Publisher · View at Google Scholar
  13. E. M. Kohner, “Microvascular disease: what does the UKPDS tell us about diabetic retinopathy?” Diabetic Medicine, vol. 25, supplement 2, pp. 20–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Warboys and P. A. Fraser, “Hyperglycemia attenuates acute permeability response to advanced glycation end products in retinal microvasculature,” Microvascular Research, vol. 80, no. 1, pp. 174–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., “Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial,” The Lancet, vol. 376, no. 9739, pp. 419–430, 2010. View at Publisher · View at Google Scholar
  16. Y. Ono, S. Aoki, K. Ohnishi, T. Yasuda, K. Kawano, and Y. Tsukada, “Increased serum levels of advanced glycation end-products and diabetic complications,” Diabetes Research and Clinical Practice, vol. 41, no. 2, pp. 131–137, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Dai, X.-B. Xia, and S.-Q. Xiong, “BDNF regulates GLAST and glutamine synthetase in mouse retinal Müller cells,” Journal of Cellular Physiology, vol. 227, no. 2, pp. 596–603, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Behl, I. Kaur, and A. Kotwani, “Implication of oxidative stress in progression of diabetic retinopathy,” Survey of Ophthalmology, vol. 61, no. 2, pp. 187–196, 2016. View at Google Scholar
  19. Y. Li, F. Zhang, N. Nagai et al., “VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats,” The Journal of Clinical Investigation, vol. 118, no. 3, pp. 913–923, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Miyamoto, S. Khosrof, S.-E. Bursell et al., “Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1),” American Journal of Pathology, vol. 156, no. 5, pp. 1733–1739, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Vermes, E. Steinmetz, L. Zeyen, and E. Van der Veen, “White blood cells are rheological properties in patients with diabetic microvascular complications,” Diabetologia, vol. 30, no. 6, pp. 434–436, 1987. View at Publisher · View at Google Scholar
  22. K. Miyamoto, N. Hiroshiba, A. Tsujikawa, and Y. Ogura, “In vivo demonstration of retinal microcirculation in entrapment leukocyte increased in diabetic rats,” Investigative Ophthalmology & Visual Science, vol. 39, no. 11, pp. 2190–2194, 1998. View at Google Scholar
  23. H. Funatsu, H. Yamashita, S. Nakamura et al., “Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema,” Ophthalmology, vol. 113, no. 2, pp. 294–301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. E. A. Pierce, R. L. Avery, E. D. Foley, L. P. Aiello, and L. E. H. Smith, “Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 3, pp. 905–909, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. D. W. Dawson, O. V. Volpert, P. Gillis et al., “Pigment epithelium-derived factor: a potent inhibitor of angiogenesis,” Science, vol. 285, no. 5425, pp. 245–248, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Gao, Y. Li, D. Zhang, S. Gee, and C. Crosson, “Unbalanced Expression of VEGF induced retinal ischemia and neovascularization in PDF,” FEBS Letters, vol. 489, pp. 270–276, 2001. View at Google Scholar
  27. O. Arjamaa and M. Nikinmaa, “Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors,” Experimental Eye Research, vol. 83, no. 3, pp. 473–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Wang, G. Wang, and Y. Wang, “Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 148, no. 6, pp. 883–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Funatsu, H. Yamashita, K. Sakata et al., “Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema,” Ophthalmology, vol. 112, no. 5, pp. 806–816, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Cunha-Vaz, “Diabetic macular edema,” European Journal of Ophthalmology, vol. 8, no. 3, pp. 127–130, 1998. View at Google Scholar · View at Scopus
  31. M. A. Bearse Jr., Y. Han, M. E. Schneck, and A. J. Adams, “Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram,” Investigative Ophthalmology & Visual Science, vol. 45, no. 1, pp. 296–304, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. P.-H. Peng, H.-S. Lin, and S. Lin, “Nerve fibre layer thinning in patients with preclinical retinopathy,” Canadian Journal of Ophthalmology, vol. 44, no. 4, pp. 417–422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. E. L. Fletcher, J. A. Phipps, M. M. Ward, T. Puthussery, and J. L. Wilkinson-Berka, “Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy,” Current Pharmaceutical Design, vol. 13, no. 26, pp. 2699–2712, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Mohr, A. Xi, J. Tang, and T. S. Kern, “Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients,” Diabetes, vol. 51, no. 4, pp. 1172–1179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Feng, Y. Wang, L. Li et al., “Gene expression profiling of vaso-regression in the retina-involvement of microglial cells,” PLoS ONE, vol. 6, no. 2, Article ID e16865, 2011. View at Publisher · View at Google Scholar
  36. H. Kettenmann, U.-K. Hanisch, M. Noda, and A. Verkhratsky, “Physiology of microglia,” Physiological Reviews, vol. 91, no. 2, pp. 461–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Saijo and C. K. Glass, “Microglial cell origin and phenotypes in health and disease,” Nature Reviews Immunology, vol. 11, no. 11, pp. 775–787, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. B. Graeber, W. Li, and M. L. Rodriguez, “Role of microglia in CNS inflammation,” FEBS Letters, vol. 585, no. 23, pp. 3798–3805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Omri, F. Behar-Cohen, Y. De Kozak et al., “Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCζ in the Goto Kakizaki rat model,” American Journal of Pathology, vol. 179, no. 2, pp. 942–953, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Ambrosini and F. Aloisi, “Chemokines and glial cells: a complex network in the central nervous system,” Neurochemical Research, vol. 29, no. 5, pp. 1017–1038, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Vujosevic, A. Micera, S. Bini, M. Berton, G. Esposito, and E. Midena, “Proteome analysis of retinal glia cells-related inflammatory cytokines in the aqueous humour of diabetic patients,” Acta Ophthalmologica, vol. 94, no. 1, pp. 56–64, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. P. J. Khandelwal, A. M. Herman, and C. E.-H. Moussa, “Inflammation in the early stages of neurodegenerative pathology,” Journal of Neuroimmunology, vol. 238, no. 1-2, pp. 1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. P. A. Campochiaro, “Ocular neovascularization,” Journal of Molecular Medicine, vol. 91, no. 3, pp. 311–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. W. Stewart, “The expanding role of vascular endothelial growth factor inhibitors in ophthalmology,” Mayo Clinic Proceedings, vol. 87, no. 1, pp. 77–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. U. Schmidt-Erfurth, G. E. Lang, F. G. Holz et al., “Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study,” Ophthalmology, vol. 121, no. 5, pp. 1045–1053, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. M. J. Elman, L. P. Aiello, R. W. Beck et al., “Randomized trial evaluating ranibizumab and prompt or deferred laser or triamcinolone and prompt laser for diabetic macular edema,” Ophthalmology, vol. 117, no. 6, pp. 1064–1077, 2010. View at Publisher · View at Google Scholar
  49. M. J. Elman, N. M. Bressler, H. Qin et al., “Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 609–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. R. K. Maturi, L. Bleau, J. Saunders, M. Mubasher, and M. W. Stewart, “A 12-Month, Single-Masked, Randomized Controlled Study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy,” Retina, vol. 35, no. 8, pp. 1604–1614, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Dutra Medeiros, M. Postorino, R. Navarro, J. Garcia-Arumí, C. Mateo, and B. Corcóstegui, “Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema,” Ophthalmologica, vol. 231, no. 3, pp. 141–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Yang, C. Bailey, F. G. Holz et al., “Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants,” Eye, vol. 29, pp. 1173–1180, 2015. View at Publisher · View at Google Scholar
  53. P. A. Pearson, T. L. Comstock, M. Ip et al., “Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial,” Ophthalmology, vol. 118, no. 8, pp. 1580–1587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., “Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE,” Ophthalmology, vol. 119, no. 4, pp. 789–801, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. C. C. Wykoff, M. J. Elman, C. D. Regillo, B. Ding, N. Lu, and I. Stoilov, “Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials,” Ophthalmology, vol. 123, no. 8, pp. 1716–1721, 2016. View at Publisher · View at Google Scholar
  56. D. V. Do, Q. D. Nguyen, R. Vitti et al., “Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti–vascular endothelial growth factor treatment,” Ophthalmology, vol. 123, no. 4, pp. 850–857, 2016. View at Publisher · View at Google Scholar
  57. Diabetic Retinopathy Clinical Research Network, J. A. Wells, A. R. Glassman et al., “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema,” The New England Journal of Medicine, vol. 372, no. 13, pp. 1193–1203, 2015. View at Publisher · View at Google Scholar
  58. J. A. Wells, A. R. Glassman, A. R. Ayala et al., “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial,” Ophthalmology, vol. 123, no. 6, pp. 1351–1359, 2016. View at Publisher · View at Google Scholar
  59. D. Grover, T. J. Li, and C. C. Chong, “Intravitreal steroids for macular edema in diabetes,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD005656, 2008. View at Google Scholar · View at Scopus
  60. S. H. Byeon, Y. K. Chu, Y. T. Hong, M. Kim, H. M. Kang, and O. W. Kwon, “New insights into the pathoanatomy of diabetic macular edema: angiographic patterns and optical coherence tomography,” Retina, vol. 32, no. 6, pp. 1087–1099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Otani, S. Kishi, and Y. Maruyama, “Patterns of diabetic macular edema with optical coherence tomography,” American Journal of Ophthalmology, vol. 127, no. 6, pp. 688–693, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Vujosevic, M. Varano, C. Egan et al., “Relevance of retinal thickness changes in the OCT inner and outer rings to predict progression to clinical macular edema: an attempt of composite grading of macular edema,” Ophthalmic Research, vol. 55, no. 1, pp. 19–25, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Baget-Bernaldiz, Resposta electroretinogràfica obtinguda en pacients diabètics tipus 2 amb edema macular difús tractats amb ranibizumab [Ph.D. thesis], University Rovira & Virgili, Tarragona, Spain, 2014.
  64. S. Vujosevic, M. Berton, S. Bini, M. Casciano, F. Cavarzeran, and E. Midena, “Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema,” Retina, vol. 36, no. 7, pp. 1298–1308, 2016. View at Publisher · View at Google Scholar
  65. G. Coscas, F. Coscas, S. Vismara, A. Zourdani, and C. I. Li Calzi, “Clinical features and natural history of AMD,” in Optical Coherence Tomography in Age-Related Macular Degeneration, G. Coscas, F. Coscas, S. Vismara, A. Zourdani, and C. I. Li Calzi, Eds., pp. 171–194, Springer, Heidelberg, Germany, 2009. View at Publisher · View at Google Scholar
  66. G. Coscas, U. De Benedetto, F. Coscas et al., “Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration,” Ophthalmologica, vol. 229, no. 1, pp. 32–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Bolz, U. Schmidt-Erfurth, G. Deak et al., “Diabetic Retinopathy Research Group Vienna Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema,” Ophthalmology, vol. 116, pp. 914–920, 2009. View at Google Scholar
  68. A. Uji, T. Murakami, K. Nishijima et al., “Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema,” American Journal of Ophthalmology, vol. 153, no. 4, pp. 710–717.e1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Framme, P. Schweizer, M. Imesch, S. Wolf, and U. Wolf-Schnurrbusch, “Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema,” Investigative Ophthalmology & Visual Science, vol. 53, no. 9, pp. 5814–5818, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Vujosevic, M. Berton, S. Bini, M. Casciano, F. Cavarzeran, and E. Midena, “Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema,” Retina, vol. 36, no. 7, pp. 1298–1308, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Vujosevic and E. Midena, “Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and müller cells alterations,” Journal of Diabetes Research, vol. 2013, Article ID 905058, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. H.-Y. Zeng, W. R. Green, and M. O. M. Tso, “Microglial activation in human diabetic retinopathy,” Archives of Ophthalmology, vol. 126, no. 2, pp. 227–232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. X. Chen, H. Zhou, Y. Gong, S. Wei, and M. Zhang, “Early spatiotemporal characterization of microglial activation in the retinas of rats with streptozotocin-induced diabetes,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 253, no. 4, pp. 519–525, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. J.-W. Kang, H. Chung, and H. C. Kim, “Correlation of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema,” Retina, vol. 36, no. 9, pp. 1630–1639, 2016. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Gaucher, C. Sebah, A. Erginay et al., “Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 289–296.e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. G. G. Deák, M. Bolz, M. Ritter, S. Prager, T. Benesch, and U. Schmidt-Erfurth, “A systematic correlation between morphology and functional alterations in diabetic macular edema,” Investigative Ophthalmology & Visual Science, vol. 51, no. 12, pp. 6710–6714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Gungel and C. Altan, “The relationship between fundus fluorescein angiographic findings and serous macular detachment in diabetic macular edema,” Retina, vol. 33, no. 9, pp. 1895–1901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Shukla, U. C. Behera, S. Chakraborty, R. Mahalakshmi, and N. M. Prasad, “Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection,” Ophthalmic Surgery Lasers and Imaging, vol. 40, no. 2, pp. 115–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. H. R. Novonty and D. L. Alvis, “A method of photographing fluorescein in circulating blood in the human retina,” Circulation, pp. 24–82, 1961. View at Google Scholar
  80. M. R. K. Mookiah, U. R. Acharya, H. Fujita et al., “Application of different imaging modalities for diagnosis of Diabetic Macular Edema: a review,” Computers in Biology and Medicine, vol. 66, pp. 295–315, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. E. D. Cole, E. A. Novais, R. N. Louzada, and N. K. Waheed, “Contemporary retinal imaging techniques in diabetic retinopathy: a review,” Clinical & Experimental Ophthalmology, vol. 44, no. 4, pp. 289–299, 2016. View at Publisher · View at Google Scholar
  82. N. Takase, M. Nozaki, A. Kato, H. Ozeki, M. Yoshida, and Y. Ogura, “Enlargement of foveal avascular zone in diabetic eyes evaluated by en face optical coherence tomography angiography,” Retina, vol. 35, no. 11, pp. 2377–2383, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. D. R. Matsunaga, J. J. Yi, L. O. De Koo, H. Ameri, C. A. Puliafito, and A. H. Kashani, “Optical coherence tomography angiography of diabetic retinopathy in human subjects,” Ophthalmic Surgery Lasers and Imaging Retina, vol. 46, no. 8, pp. 796–805, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. P. D. Bradley, D. A. Sim, P. A. Keane et al., “The evaluation of diabetic macular ischemia using optical coherence tomography angiography,” Investigative Ophthalmology and Visual Science, vol. 57, no. 2, pp. 626–631, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. T. S. Hwang, S. S. Gao, L. Liu et al., “Automated quantification of capillary nonperfusion using optical coherence tomography angiography in diabetic retinopathy,” JAMA Ophthalmology, vol. 134, no. 4, pp. 367–373, 2016. View at Publisher · View at Google Scholar